Holen Sie sich die Stockscreener-App
13.80
1.77%
0.24
Handel nachbörslich:
13.80
Schlusskurs vom Vortag:
$13.56
Offen:
$13.73
24-Stunden-Volumen:
1.24M
Relative Volume:
0.82
Marktkapitalisierung:
$839.48M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-113.63M
KGV:
-7.527
EPS:
-1.8334
Netto-Cashflow:
$-83.28M
1W Leistung:
-0.43%
1M Leistung:
+0.73%
6M Leistung:
-36.61%
1J Leistung:
-55.24%
1-Tages-Spanne:
$13.62
$14.10
1-Wochen-Bereich:
$13.46
$14.31
52-Wochen-Spanne:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.80 | 824.88M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Does Janux Therapeutics (NASDAQ:JANX) Show Signs of Market Sensitivity? - Kalkine Media
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
D-Wave Quantum: Die bittere Wahrheit! - Finanztrends
Advanced Renal Cell Carcinoma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeuti - Barchart.com
The Technical Signals Behind (JANX) That Institutions Follow - Stock Traders Daily
Precision Trading with Janux Therapeutics Inc. (JANX) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Veeva Systems (VEEV) and Janux Therapeutics Inc (JANX) - The Globe and Mail
HC Wainwright Expects Higher Earnings for Janux Therapeutics - MarketBeat
JANX PE Ratio & Valuation, Is JANX Overvalued - Intellectia AI
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring The 316.79% Potential Upside - DirectorsTalk Interviews
JANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Truist cuts Janux Therapeutics stock price target on competition By Investing.com - Investing.com Canada
Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating - marketscreener.com
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating - TipRanks
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Bitget
Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial - Finviz
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st
Key facts: Janux Therapeutics Receives Strong Buy Ratings; Partners with BMS - TradingView
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating - TipRanks
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Guggenheim Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux Therapeutics, Inc. Q4 Loss Rises - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Janux Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q4 Revenue $0 - marketscreener.com
Bristol Myers deal and wider 2025 loss at Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51 - TradingView
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Technical Reactions to JANX Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS) - The Globe and Mail
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring A 376% Upside In Biotechnology - DirectorsTalk Interviews
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN) - The Globe and Mail
Why analysts remain bullish on Janux Therapeutics Inc. stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - mfd.ru
Where is Janux Therapeutics (JANX) Headed According to Analysts? - Finviz
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Masimo (MASI), Janux Therapeutics Inc (JANX) and Beta Bionics, Inc. (BBNX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Janux Therapeutics Inc (JANX) and BioLife Solutions (BLFS) - The Globe and Mail
Janux therapeutics doses first participant in JANX011 phase 1 trial By Investing.com - Investing.com Australia
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - AOL.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - BioSpace
Janux therapeutics doses first participant in JANX011 phase 1 trial - Investing.com Nigeria
Janux Therapeutics, Inc. (JANX) Investor Outlook: A Potential 383.93% Upside in the Biotech Sector - DirectorsTalk Interviews
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011 - TradingView
Published on: 2026-02-15 18:41:23 - mfd.ru
Trading the Move, Not the Narrative: (JANX) Edition - Stock Traders Daily
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):